BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25825478)

  • 1. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    Clin Cancer Res; 2015 Jul; 21(14):3187-95. PubMed ID: 25825478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
    Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.
    Walter RB; Alonzo TA; Gerbing RB; Ho PA; Smith FO; Raimondi SC; Hirsch BA; Gamis AS; Franklin JL; Hurwitz CA; Loken MR; Meshinchi S
    J Clin Oncol; 2010 Jun; 28(17):2831-8. PubMed ID: 20421533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Lamble AJ; Eidenschink Brodersen L; Alonzo TA; Wang J; Pardo L; Sung L; Cooper TM; Kolb EA; Aplenc R; Tasian SK; Loken MR; Meshinchi S
    J Clin Oncol; 2022 Jan; 40(3):252-261. PubMed ID: 34855461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia.
    Zhou M; Tong X
    Diagn Pathol; 2015 Aug; 10():147. PubMed ID: 26293996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.
    Tierens A; Bjørklund E; Siitonen S; Marquart HV; Wulff-Juergensen G; Pelliniemi TT; Forestier E; Hasle H; Jahnukainen K; Lausen B; Jonsson OG; Palle J; Zeller B; Fogelstrand L; Abrahamsson J
    Br J Haematol; 2016 Aug; 174(4):600-9. PubMed ID: 27072379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
    Ho PA; Kuhn J; Gerbing RB; Pollard JA; Zeng R; Miller KL; Heerema NA; Raimondi SC; Hirsch BA; Franklin JL; Lange B; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2011 Feb; 29(6):704-11. PubMed ID: 21189390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.
    Zhou LY; Yin JY; Tang Q; Zhai LL; Zhang TJ; Wang YX; Yang DQ; Qian J; Lin J; Deng ZQ
    Int J Clin Exp Pathol; 2015; 8(12):16073-80. PubMed ID: 26884884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
    Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
    Johnston DL; Alonzo TA; Gerbing RB; Hirsch B; Heerema NA; Ravindranath Y; Woods WG; Lange BJ; Gamis AS; Raimondi SC
    Pediatr Blood Cancer; 2013 Dec; 60(12):2073-8. PubMed ID: 24039149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
    Shi JL; Fu L; Wang WD
    Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.
    Liu L; Chen R; Zhang Y; Fan W; Xiao F; Yan X
    Diagn Pathol; 2015 Jul; 10():109. PubMed ID: 26185105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
    Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
    Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
    Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
    Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.